The exploration of the molecular mechanisms and signaling pathways on lung cancer is very important for developing new strategies of diagnosis and treatment to this disease, such as finding valuable lung cancer markers and molecularly targeted therapies. Previously, a number of studies disclose that heat shock protein 90 (Hsp90) is upregulated in cancer cells, tissues and serum of lung cancer patients, and its upregulation intimately correlates with the occurrence, development and outcome of lung cancer. On the contrary, inhibition of Hsp90 can suppress cell proliferation, motility and metastasis of lung cancer and promote apoptosis of lung cancer cells via complex signaling pathways. In addition, a series of Hsp90 inhibitors have been investigated as effective molecular targeted therapy tactics fighting against lung cancer. This review, systematically summarizes the role of Hsp90 in lung cancer, the molecular mechanisms and development of anti-Hsp90 treatment in lung cancer.
With the development of tumor molecular biology, progress of the detection and treatment of cancer has led to an impressive reduction in both mortality and morbidity. However, cancer still remains one of the most clinically challenging diseases (1). Today, it is believed that systemic chemotherapy improves the survival and quality of life of patients with advanced stage cancer, and improved the outcome of first-line therapy for advanced and metastatic cancer have primarily focused on the addition of targeted agents to platinum-based two-drug regimens (2). Medical studies suggest that understanding the molecular mechanism of tumors is critical for improving the diagnosis and treatment. Especially, the level of certain protein expression is associated with the prognosis and treatment of malignant tumors (3). Heat shock protein 90 (Hsp90) accounts for 1–2% of the amounts of cellular proteins under non-stressed conditions. However, it contents would go up approximately twice during environmental stress (4). Hsp90 performs a series of biological functions via complicated signals regulation by combining and disaggregation of ATP, and various client proteins and co-chaperones of Hsp90 are implicated in this process (5). Human Hsp90 includes four isoforms: Hsp90α and β (cytosolic isoforms), TRAP1 (in mitochondria) and Grp94 (in endoplasmic reticulum) (6). Hsp90β (Hsp90AB1) is regarded as a constitutive expression while Hsp90α (Hsp90AA1) as an inducible expression, it is proved that they have 86% amino acid sequence identity (7). Hsp90 has been found as a critical regulator of cell proliferation, development, mobility and metastasis in malignant tumors, which facilitates maturation and activation of oncogenic proteins, including many kinases and transcription regulatory factors (8). Also, Hsp90 exerts anti-apoptotic activity and affects growth processes tumor cells, and overexpression of Hsp90 has been obviously associated with drug resistance and survival time of tumor patients (9). Previous studies show that Hsp90 is highly expressed in specimens of lung cancer and are associated with poor post-surgical survival time and lymphatic metastasis of lung cancer patients (10–13) indicating that upregulation of Hsp90 potentially facilitates proliferation and metastasis of lung cancer. However, anti-Hsp90 (Hsp90 inhibitors) studies have demonstrated that downregulation and function disruption of Hsp90 inhibits cell proliferation, motility and metastasis, and induces apoptosis of lung cancer cells (11,12,14). Here, we reviewed new findings on the role of Hsp90 in lung cancer, including the mechanisms and signaling pathways, the pre-clinical results of Hsp90 inhibition (14).
2. Molecular structure and function domain of Hsp90
As a homodimeric protein of ~90 kDa, Hsp90 performs complicated biological functions reacting with many collaborating proteins (co-chaperons and clients proteins of Hsp90) (15). As shown in Fig. 1A, Hsp90α, Hsp90β, gp96 and the TRAP1 are four members of Hsp90 family (7). Different members of Hsp90 family present the same action pattern but binding to specially appointed clients proteins, which depends in part on their locations and distribution within the different cells (16). Each protomer of Hsp90 comprises three regions, ATP-binding domain (N-domain), middle domain (M-domain), and C-terminal dimerization domain (C-domain) (17) (Fig. 1B). Constructively, the 25-kDa N-terminal of Hsp90 is relatively conserved, which is linked with 55 kDa C-terminal domains by a charged linker region and middle domain (16) (Fig. 1B). The middle domain of Hsp90 is ~35 kDa, has been investigated as a binding site for client proteins and nuclear localization signal, which is implicated in recognising of collaborating proteins and adjusting the activation molecular chaperones (18) (Fig. 1B). Hsp90 exerts relevant functions via binding and hydrolysis of ATP like a molecular clamp, which facilitates the combining and dissociation of its client proteins (19) (Fig. 1B). The important two members of Hsp90, Hsp90α and Hsp90β, exist as a result of the duplication of the original gene and share 86% homology (20). In humans, the chromosome 14q32.33 encodes the Hsp90α, while Hsp90β is located at 6p21. Hsp90-coding genes include intron sequences and the second exon is the region of translational initiation of both Hsp90α and Hsp90β (7) (Fig. 1C).
3. Co-chaperons and client proteins of Hsp90Co-chaperons of Hsp90
The discovery and structural characterization of the ATP-binding site in the N-terminal domain of HSP90, made it possible to determine the degree to which the ATPase activity of HSP90 contributed to the essential biological functions of HSP90 as a molecular chaperone. There are more than 20 different proteins that regulate the activity and function of Hsp90, which are known as co-chaperones (Fig. 2A). Of them, Hop/Sti1 inhibits the activity of Hsp90 ATPase and recruits steroid hormone receptor to Hsp90 (21,22). Cdc37 helps the loading of other co-chaperones of Hsp90 (18), p23/Sba1 inhibits the ATPase activity of Hsp90 and also promotes the maturation of client proteins (22,23). PP5 stabilises the status of Hsp90 phosphorylation promoting the efficient processing of client proteins (24,25). Human peptidyl prolyl cis/trans isomerases, Fkbp51, Fkbp52 and Cyp40 improve the client protein maturation of Hsp90 (26). unc45b forms a stable complex with Hsp90 and selectively combines the myosin motor domain, and promotes motor domain folding (27). Together with the Tah1 cofactor, Hsp90 stabilize Pih1/nop17 and increases the chromatin remodeling and small nuclear ribonucleoprotein maturation (28). Aha1 induces Hsp90 rearrangements that speeds up the conformational cycle, which defines a controlled progression through distinct intermediates (29). Co-chaperones of Hsp90 are also involved in other physiological processes, such as mitochondrial/chloroplast protein import, nuclear migration and melanoma progression (30).
Client proteins of Hsp90
The client proteins of Hsp90 have been found to be related to a wide aspects of physiological procedures including the regulation of cell cycle, communication of cell signals and regulation of cell transcription and post-transcriptional adjustment (Fig. 2B). Hsp90 plays a critical role in the function and stability of ErbB2/HER2 by binding to IGF-I and TGF receptor I and II (18,31,32). The members of Src family, Yes, Fes, Fps, Abl and Lck, have been shown to be related to the exertion of Hsp90 function, which activate the cascade reaction of downstream molecules (18,33,34). Two proteins of MAPK pathway, ERK1 and ERK2 regulate the growth of cells by phosphorylating many kinds of substrates within the nucleus. In addition, Hsp90 correlates with the structure and function of Raf-1 and B-Raf by interacting with Cdc37 (18,35,36). Clearly, the activity of CK2 depends upon the appearance of Hsp90 (12,37), estrogen and androgen receptors, require the assistance of Hsp90 to enable the steroid hormone ligand to bind (16). Inhibiting Hsp90 results in the proteolysis of hTERT, which affects the function of hTERT (38,39). Downregulation of Hsp90 reduces the expression of MMP9 and protects the MMP2 from degradation in malignant cells (40,41). Also, p53 interacts with Hsp90 in a relatively folded state, which may be chalked up to the destabilization by Hsp90 (42,43). Some Hsp90 client proteins, including RAF, ErbB2, EGFR, MAK and hTERT, have been found to interact with Hsp90 and play important roles in the development of lung cancer (44,45).
4. Expression of Hsp90 in lung cancer
Table I lists the recent important findings on the expression of Hsp90 in lung cancer. Hsp90 is highly expressed in NSCLC patients, and increased Hsp90 positively correlates with age, lung squamous cell carcinoma (LSCC), ever-smoking history and metastasis of lymph node (46). Also, overexpression of Hsp90 in NSCLC patients relates with shorter overall survival (47), suggesting that it could be used to predict survival (48). In parental T2821 and T2851 cells of lung cancer, the protein expression of Hsp90 is upregulated, and in radio-resistant T2821/R and T2851/R cells lines this phenomena is eminent and intimately correlates with the radioresistance of T2821/R and T2851/R cells (49). Compared with the control cells, the expression of Hsp90 in SPCA-1 and H446 cell lines of lung cancer is upregulated remarkably, which presents a dose-dependent pattern to geranylgeranylacetone (50). High expression of Hsp90 is also associated with male patients, patients with smoking index over 600, and SCLC (51). One study reports that overall survival (OS) of high-Hsp90β expression lung cancer is shorter than that of low-Hsp90β group and Hsp90β is an independent prognostic factor (11). In addition, overexpression of Hsp90β is found in tissues of lung adenocarcinoma, which is related to the poorly differentiated grade, shorten OS (52) and lymphatic invasion (10). Increased serum Hsp90β correlates with the differentiated grade and advanced clinical stage of patients with lung cancer, and assists the diagnosis and prognosis estimation (13). In one comparative study, Hsp90β in lung cancer tissues showed a higher expression than that in normal lung tissue and Hsp90β presents a higher expression in LAC tissues than in LSCC, and correlates with the poor survival of LAC patients (53). A study with a total of 2,247 individuals demonstrates that the plasma Hsp90α of lung cancer patients has a significantly higher level and correlates with advanced stage of lung cancer patients (stage III–IV) (54).
Currently, there are still some limitations on investigating the expression of Hsp90 in lung cancer. First, we still lack large number of samples and multiple center research. There is no high quality research concerning the expression of Hsp90 in lung tissues, blood, BALF, and malignant pleural effussion (MPE). Second, previous studies do not focus on Hsp90 gene mutations and abnormal copy. Because a great deal of studies on inhibitors of Hsp90 that fight against lung cancer show that not all lung cancer respond with definite efficacy to inhibitors of Hsp90.
5. Biological functions of Hsp90 in lung cancer
From 2000 to now, investigating the relation between Hsp90 and lung cancer has become a very active field, especially on the efficacy of Hsp90 inhibitors that fight against lung cancer. It seems that different Hsp90 inhibitors affect different signaling pathways via specific signal molecules in development of lung cancer.
Influence of Hsp90 on cell cycle regulation and cell apoptosis of lung cancer
As shown in Fig. 3, Hsp90 inhibitor FS-108 induces G2/M phase arrest of gefitinib-resistant lung cancer cells by reducing the expression of Cdc2 and Cdc25C, and promotes apoptosis of gefitinib-resistant cells via a caspase-dependent pathway (55). STA-8666 combines a chemical moiety targeting active Hsp90 fused via cleavable linker to the active metabolite of irinotecan (SN38), and induces cell cycle arrest, associating with DNA damage and cell cycle checkpoints, and apoptosis (56). Hsp90 inhibitor 17-AAG arrests cell cycles of lung cancer A549 and H446 cells at the G2/M phase and promotes apoptosis via regulating the expression of apoptosis-related proteins (Bax and Bcl-2) (57), and combination of 17-AAG and carbon ions shows treatment efficacy in lung cancer, which results in a definite G2 cell cycle delay (58). Geldanamycin and 17-AAG inhibit the growth of lung cancer cell lines via inducing G2/M arrest concomitant with decreased protein levels of Cdc25C and Cdc2 (51). CDBT exerts an antitumor activity in P-gp overexpressing drug-resistant NSCLC H460TaxR cells by the destabilization of microtubules, degradation of CRAF-1 and ErbB2 and phosphorylated AKT (44), leading to cell cycle arrest at the G2/M phase and reinforcement of apoptosis (59). Hsp90 inhibition of IPI-504 results in disruption of EML4-ALK and inhibition of its downstream signaling pathways, which induces growth arrest and apoptosis in cells carrying the EML4-ALK fusion (60). Hsp90 inhibitor PU-H71 upregulates Grp94, Grp78, ATF4 and CHOP, inducing apoptosis of lung cancer cells by downregulation of Bcl-2, upregulation of Bax, release of cytochrome c and activation of caspases (61).
Hsp90 regulates the growth of lung cancer via EGFR-related signaling pathways
As shown in Fig. 4, Hsp90 inhibitor, 2′,4′-dimethoxychalcone (1b) suppresses the growth of Iressaresistant NSCLC H1975 cells by downregulating EGFR, Met, Her2, AKT, and Cdk4, and upregulating Hsp70 (62). Hsp90 inhibitor AUY922 inhibits the proliferation of lung cancer cells and induces cell death by downregulation of EGFR, Met, and AXL, leading to disruption of AKT signal (63). Furthermore, AUY922 results in obvious exhaustion of EGFR, Met, HER2 and AKT in NSCLC cell lines, giving rise to a reinforcement of apoptosis (64). Hsp90 inhibitor WK88-1 reduces the cell survival of lung cancer cells via reducing the expression of EGFR, ErbB2, ErbB3, Met and Akt (65), and combination treatment of Hsp90 inhibitor ganetespib and erlotinib stabilizes the expression state of EGFR inactivation and disrupts ERK and AKT signaling activity (66). Hsp90 inhibitor 17-DMAG inhibits the growth of Ma-1/HGF cells, H1975 cells and PC-9 cells by downregulating EGFR and Met (67) and exhausting EGFR, AKT, MAPK, Cdk4, and cyclin D1 in EGFR-mutant cell lines (68). Hsp90 inhibitors SNX-2112 and SNX-5422 alone and in combination with erlotinib suppresses EGF activation of pAKT(473) and pSTAT3(705), pERK1/2 and pS6 and decreases EGF cross-talk and activation of the c-Met receptor (69). Gamabufotalin inhibits the chaperone function of Hsp90 by reducing expression of Hsp90-dependent client protein EGFR (45). Hsp90 inhibitor HDN-1 binds to C-terminus of Hsp90α and degrades multiple oncoproteins, promoting EGF-induced wild-type and mutated EGFR down-regulation (70).
Hsp90 regulates the growth of lung cancer via RAS-RAF-MEK-ERK-MAPK, PI3K/AKT, TGF and VEGF signaling pathways
As shown in Fig. 5, Hsp90 inhibitor AUY922 inhibits the signals of PI3K-AKT-mTOR and RAF-MEK-ERK and exerts antitumor activity (71). 17-DMAG reduces the survival of SCLC cell lines via downregulating proto-oncogene c-RAF (72) and also reduces XRCC1 expression via inactivation of ERK1/2 and AKT enhancing antitumor activity of gefitinib (73). Defects or polymorphisms of MSH2 correlates with lung cancer, 17-AAG leads to enhanced cytotoxic effect accompanied by the reduction of MSH2 via downregulation of the MKK3/6-p38 MAPK signal and inactivation of p38 MAPK (74). In addition, 17-AAG leads to a decrease of cellular thymidine phosphorylase via ubiquitin-26S proteasome pathway with downregulation of phosphorylated MKK1/2-ERK1/2 and AKT protein levels (75). Hsp90 inhibitor CUDC-305 leads to the degradation of RTKs, and disrupts the signaling molecules of the PI3K/AKT and RAF/MEK/ERK pathways, with concurrent induction of apoptosis (76). Hsp90 inhibitor deguelin reveals an anti-Hsp90 activity and keeps a lid on the expression of a number of client proteins of Hsp90, which is involved in the PI3K/AKT pathway (77). Inhibition of Hsp90 by CS-6 prohibits lung cancer growth by targeting IKKβ/NF-κB, which reduces the expressions of hTERT, HIF-1α, VEGF, CDK4, HER2, p-Akt, cyclin D1, p110α and p-p85 (45). Hsp90 inhibitor L80 disrupts the correlation of HIF-1α and Hsp90 by reducing HIF-1α, VEGF and IGF2 (78). Hsp90 inhibition by CH5164840 with erlotinib treatment abolishes phosphorylation of Stat3 in lung cancer cells, which downregulates ERK signaling (79). Repair protein Rad51 protects NSCLC cells against chemotherapeutic cytotoxicity, but Hsp90 inhibitor 17-AAG cuts down the levels of Rad51 and decreases the phosphorylation of MKK1/2-ERK1/2 (80). Furthermore, Hsp90 inhibition caused by ganetespib shows an obvious cell killing in lung cancer cells, with concomitant destabilization of KRAS signaling effectors, and combination of ganetespib and MEK or PI3K/mTOR inhibitors leads to a remarkable cytotoxic activity (81).
Some new molecular signals involved in network of Hsp90 in lung cancer
As shown in Fig. 6, Hsp90 inhibitor 17-AAG downregulates the expression of MSH2 in human lung cancer and its combination with tamoxifen reinforces cytotoxicity and cell growth inhibition synergistically via reducing MSH2 expression (82). As a potent proteasome inhibitor, PS-341 inhibits various types of cancer, interestingly, Hsp90 inhibitor 17-AAG enhances PS-341-induced lung cancer cell death by degrading upstream regulators of IκB, IRAK-1, and IκB kinases (IKKs) (83). In addition, combination of 17-DMAG and TNF brings about synergistic killing of lung cancer cells via downregulation of IKKβ (84). Hsp90 inhibitor ganetespib induces loss of EML4-ALK expression and depletion of multiple oncogenic signaling proteins in ALK-driven NSCLC cells (85). Inhibition of Hsp90 by NVP-AUY922 suppresses the growth of NSCLC cells, which involves a wide range of cellular functions via consistently decreasing the levels of dihydrofolate reductase (86). Cellular FLICE-inhibitory protein (long form, c-FLIPL) is a critical negative regulator of death receptor-mediated apoptosis, however, depletion of Hsp90α/β decreases c-FLIPL level, and combination of 17-AAG and celecoxib reinforces this results by caspase activation (87). Ganetespib blocks Hsp90 to bind to biotinylated geldanamycin and disintegrates the relation of Hsp90 with its co-chaperone, p23, which inhibits the growth of lung cancer (88). Hsp90 inhibitor deguelin binds to the ATP-binding pocket of Hsp90 and disrupts Hsp90 function by ubiquitin-mediated degradation of HIF-1α (89). Moreover, combination of 17-AAG and TNF induces apoptosis-related cell death of lung cancer cells by degrading RIP and IKKβ that, in turn, blocks TNF-induced NF-κB activation (90).
6. Hsp90-dependent radiosensitization in treatment of lung cancer
The combined treatment of Hsp90 inhibitors and conventional photon radiation has shown more effective tumor growth inhibition than radiation alone, and a number of Hsp90 inhibitors are also known to sensitize cancer cells to radiation. Hsp90 inhibitor ganetespib sensitizes NSCLC cells to radiation (91) via potentiating the effect of radiotherapy and eliminating radioresistant residual cells (49). A purine-scaffold Hsp90 inhibitor, PU-H71, promotes the sensitivity of the lung cancer cells to radiation by inhibiting the repair of DSBs (92). 17-AAG and 17DMAG (Hsp90 inhibitors) have been reported to be potent radio-sensitisers, achieving radiation enhancement ratios ranging from 2.3 to 2.7 (93). Co-treatment of 17-DMAG with radiation has a synergistic antitumor activity in NSCLC cells, which involves in inhibition of DNA repair and correlates with the BER and ATM-regulated pathways (94). Combination of irradiation and 17-AAG displays an additive effect on cell growth inhibition by downregulating the expressions of Cdc25C and Cdc2 (51). Hsp90 inhibitor NVP-AUY922 results in radiosensitization, which is accompanied by DNA repair effect, cell cycle progression and abrogation of homologous recombination (95). Co-treatment of NVP-AUY922 and 17-AAG leads to upregulation of HIF-1α and thus shows a promotion of radiosensitivity (96). Especially, celastrol disrupts the ATP-binding activity of Hsp90, and thus reinforces the radiation-induced cell killing by decreasing levels of EGFR, ErbB2 and survivin and increasing p53 expression (97). Hsp90 inhibitor deguelin suppresses radioresistant lung cancer cells and combined treatment of radiation with deguelin cuts down the viability and vascularization of radioresistant cells by blocking the HIF-1α/Hsp90 interaction and HIF-1α expression (98).
7. Hsp90 and drug resistance of lung cancerHsp90 and drug resistance of traditional chemotherapy
As shown in Table II, upregulated Hsp90 has been investigated in connection with the chemoresistance to cisplatin in LAC cells (50), however, inhibition of Hsp90 increases the sensitivity of cells to cisplatin by inducing AMH and AMHR2 expression (99). Hsp90 inhibitor 17-AAG increases the cisplatin-induced cell-killing via suppressing TP expression and activation of ERK1/2 and AKT (75). Hsp90 inhibitor L80 suppresses the proliferation, survival, and migration of lung cancer cells acquired resistance to paclitaxel (78). Hsp90 inhibitor ganetespib facilitates the cell-killing activity of paclitaxel and docetaxel in NSCLC models (100) and 17-AAG reinforces the cytotoxic effect of etoposide by inhibiting the expression of ERCC1 (101). Also, Hsp90 inhibitor STA-8666 combines a chemical moiety targeting active Hsp90 fused via cleavable linker to active metabolite of irinotecan SN38, thus strongly promotes the antitumor activity of carboplatin (56).
Hsp90 and drug resistance of molecular targeted therapy
As shown in Table II, some Hsp90 inhibitors show activity of reversing molecular targeting drug resistance and synergism. FS-108 circumvents gefitinib resistance in EGFR mutant NSCLC cells through inducing G2/M phase arrest and apoptosis (55). AUY922 inhibits growth of EGFR-TKI resistant cell lines by inducing cell programmed death (63) and also displays activity against the gefitinib-resistant sublines with T790M mutation and Met amplification (102). WK88-1 reverses gefitinib resistance by interfering the EGFR or c-Met stability and functions (65). 17-AAG represents a better efficacy for treating NSCLC with acquired resistance to EGFR TKIs (103) and the combination of gefitinib and 17-AAG increases NSCLC cell growth inhibition (73). SH-1242 targets those cells that are chemoresistant or harbor KRAS mutations (104) and exerts cytotoxicity to lung cancer cells. Pyruvate kinase M2 (PKM2) interacts with mutant EGFR and Hsp90 contributing to EGFR-dependent tumorigenesis and facilitates to overcome drug resistance to EGFR TKIs (105). 2′,4′-dimethoxychalcone (1b) restrains the proliferation of iressa-resistant NSCLC cells by circumventing the drug-resistance acquired by Met amplification and EGFR mutations (62). Ganetespib shows a remarkable ability to defeat multiple forms of crizotinib resistance, including secondary ALK mutations (85). 17-DMAG can circumvent both primary and acquired crizotinib resistance (106). Ganetespib promotes the antitumor activity of erlotinib in erlotinib-resistant NCI-H1975 xenografts and also increases efficacy of afatinib (66). CH5164840 can increase the anticancer activity of erlotinib against NCI-H292 EGFR-overexpressing xenograft models (79). CUDC-305 induces apoptosis and inhibits cancer growth of erlotinib-resistant NSCLC cells (76). CDBT has been discovered to have a potent activity against P-gp overexpressing drug-resistant NSCLC H460TaxR cells (59). Hsp90 inhibitors also overcome ligand-triggered resistance to new generation ALK inhibitors and may bring improved benefit for NSCLC patients with EML4-ALK (107,108).
8. Clinical research on Hsp90 inhibitors for treating lung cancer
The potential anticancer activity of some Hsp90 inhibitors for treating lung cancer has been proven in preclinical in vitro and in vivo models. For instance, recently a clinical trial evaluated the activity and safety of Hsp90 inhibitor ganetespib in combination with docetaxel in advanced NSCLC, which showed that combination of ganetespib significantly prolongs the PFS and OS and the combination treatment of ganetespib and docetaxel does not have obvious additional side effects (109). NSCLC patients in a previous study were divided into three groups: cohort A (EGFR mutants), B (KRAS mutants), or C (with out mutations of both). Patients of the three groups were all administered ganetespib of 200 mg/m2 via intravenous infusion (1/week; rest for a week after 3 weeks), until disease progression. The results showed that ganetespib monotherapy presents a manageable side effect profile as well as clinical activity in heavily pretreated patients with advanced NSCLCs, particularly in patients with tumors harboring ALK gene rearrangement (110). Another prospective, non-randomized, multicenter, phase II study of IPI-504 monotherapy has shown that IPI-504 has certain clinical activity in patients with NSCLC, particularly among patients with ALK rearrangements (111). However, the clinical research on the Hsp90 inhibitor for treating lung cancer is only at the beginning, it seems that these studies did not produce an impressive breakthrough as we expected. Because Hsp90 conduces to the maturation and stability many mutated or overexpressed oncogenic proteins, targeting Hsp90 has been considered as an effective anticancer therapy. Although the WCLC2016, GALAXY-2 study showed that the addition of ganetespib as a rescue treatment on the basis of docetaxel did not improve efficacy. The combination application of Hsp90 inhibitors and other traditional chemotherapy is still greatly worthy of further exploration. However, the clinical research of Hsp90-dependent molecular targeted therapy (Hsp90 inhibitors) is an area where we have really fallen far behind. We must acknowledge that the main reason of leading to the embarrassing situation correlates with medical ethics and strict approval system of new drugs in all countries; after all, we are faced with humans. However, clinical research and application is the only way and the ultimate goal. Only this way, can we bring benefits to lung cancer patients from Hsp90 inhibitors.
9. Perspective and limitation
The clinical benefit of current anticancer regimens for lung cancer therapy is still limited due to moderate efficacy, drug resistance, and early recurrence. Therefore, the development of effective new anticancer drugs for first-line therapy and for optimal second-line treatment is necessary. Study on the molecular mechanism of Hsp90 in lung cancer has made some progress as well as greatly promoting the development of Hsp90-dependent molecular targeted drugs. However, there are some shortcomings in current research. So far, no large sample numbers and multiple centers on the expression of Hsp90 in lung cancer are reported, including in lung tissues, blood, bronchoalveolar lavage fluid and malignant pleural effussion. In addition, no studies keep a watchful eye on gene mutations and copy abnormality of Hsp90, which may be correlated with the efficacy of Hsp90 inhibitors such as EGFR mutations. Importantly, although clinical studies to evaluate the activity and safety of Hsp90 inhibitors in treating lung cancer patients has been reported occasionally, it seems that quality and scale of these studies could not support the evidence of clinical application of Hsp90 inhibitors. To assess whether Hsp90 inhibitor proves to be a successful therapeutic strategy in treating lung cancer patients, we still need to do further research, such as construction of drug delivery vehicles, design of clinical research and evaluation of side effects. Future research should focus on assessing the activity and safety of Hsp90 inhibitors in clinical lung cancer patients and establish the most effective Hsp90 inhibitors for treating lung cancer.
10. Conclusion
Research shows that Hsp90 is highly expressed in lung cancer and that upregulation of Hsp90 potentially facilitates proliferation and metastasis of lung cancer. However, anti-Hsp90 (Hsp90 inhibitors) studies have demonstrated that downregulation and function disruption of Hsp90 inhibits cell proliferation, motility and metastasis, and induces apoptosis of lung cancer cells. However, there is an urgent need for a comprehensive assessment of Hsp90 protein expression and gene abnormality in large cohorts of lung cancer. In addition, high quality clinical research on Hsp90 inhibitors are also needed for evaluating the efficacy and safety in clinical recommendation. Actually, we still know relatively little as to how the Hsp90 regulates tumorigenesis of lung cancer at the molecular level, thus improved understanding of the molecular mechanisms and signaling pathways correlated with Hsp90 present an interesting challenge, and a future important direction.
Acknowledgments
This study was supported by grants from the Scientific Research Plan projects of Shaanxi Province Education Department (no. 17JK0661).
Abbreviations17-AAG
Hsp90 inhibitor
17-DMAG
17-demethoxygeldanamycin
Hsp90
inhibitor
Abl
Src family tyrosine kinase
Aha1
activator of Hsp90 ATPase
AKT
anaplastic lymphoma kinase
ALK3
AMHR2 heterodimerizes with type I receptors
AMH
anti-Müllerian hormone
AMHR2
anti-Müllerian hormone type II receptor
APC/C
anaphase promoting complex
ATF4
anti-activating transcription factor 4
AT13387
Hsp90 inhibitor
ATM
ataxia-telangiectasia mutant
ATP
adenosine-triphosphate
ATPase
adenosinetriphosphatease
AUY922
Hsp90 inhibitor
AXL
receptor tyrosine kinase
BAD
Bcl-2-associated death promoter
BALF
bronchoalveolar lavage fluid
Bcl-2
B-cell lymphoma-2
Bax
bcl-2-like protein 4
BER
base excision repair
BMP
bone morphogenetic protein
Cdc2
cell division cycle 2
CDBT
Hsp90 inhibitor
Cdc25C
cell division cycle 25C
Cdc37
cell division cycle 37
Cdk
cyclin-dependent kinase
c-FLIPL
cellular FLICE-inhibitory protein
CHOP
nuclear transcription factor
CH5164840
Hsp90 inhibitor
CK2
casein kinase 2
COX-2
cyclooxy-genase-2
CRAF-1
threonine protein kinase
CS-6
Hsp90 inhibitor
Cyp40
cyclophilin 40
CUDC-305
Hsp90 inhibitor
DSBs
DNA double-strand breaks
EGF
epidermal growth factor
EGFR
epidermal growth factor receptor
EML4-ALK
echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase
EMT
epithelial-mesenchymal transition
ER
estrogen receptor
ErbB2/HER2
human epidermal growth factor receptor-2
ERBB2 YVMA
a 12-bp duplication/insertion of the amino acid sequence YVMA in exon 20 at codon 776
ERCC 1
excision repair cross-complementary 1
ERK
extracellular-signal-regulated kinase
FAK
focal adhesion kinase
Fes
Src family tyrosine kinase
Fkbp51
Hsp90-associated human peptidyl prolyl cis/trans isomerases
Fkbp52
Hsp90-associated human peptidyl prolyl cis/trans isomerases
Fps
Src family tyrosine kinase
FS-108
Hsp90 inhibitor
Gp96
a receptor for heat shock protein 90
Grp94
glucose-regulated protein 94
Grp78
glucose-regulated protein 78
HDAC6
histone deacetylase 6
HDACi
histone deacetylase inhibitor
HDN-1
Hsp90 inhibitor
HEY-1
hairy/ enhancer-of-split related with YRPW motif protein 1
Her2
human epidermal growth factor receptor-2
HES-1
Hes family BHLH transcription factor 1
HGF
hepatocyte growth factor
HIF-1α
hypoxia-inducible factor-1
Hop/Sti1
hop-like stress-induced protein 1 co-chaperone
Hsp90
heat shock protein 90
hTERT
human telomerase reverse transcriptase
IGF-I
insuliN-like growth factor 1
IGF2
insulin-like growth factor 2
IκB
IκB kinases
IKKβ
inhibitor of nuclear factor κB kinase
IKKs
inhibit κB kinase complex
IPAK-1
Toll-like receptor-associated kinases
IPI-504
Hsp90 inhibitor
IL-1R
interleukin-1 receptor
IRAK-1
IL-1R-associated kinase-1
kDa
atomic mass unit
Lck
Src family tyrosine kinase
LAC
lung adenocarcinoma
L80
Hsp90 inhibitor
L858R
leucine substitution at amino acid 858
LPLTPLP
Hsp90 inhibitor
MAPK
mitogen-activated protein kinase
MEK
mitogen-activated protein kinase/extracellular signal-regulated kinase kinase
Met
Met gene
MKK
a dual-specificity protein kinase of the STE7 family
MMP
matrix metalloproteinase
MPE
malignant pleural effussion
MSH2
human MutS homolog 2
NF-κB
nuclear factor κB
NVP-AUY922
Hsp90 inhibitor
NSCLC
non-small cell lung cancer
OS
overall survival
p110α
enhanced phosphoinositide 3-kinase
p23/ Sba1
the protein encoded by the PTGES3 gene
p53
tumor suppressor
p65
transcription factor
P-gp
P-glycoprotein
PKM2
pyruvate kinase M2
PI3K
phosphatidylinositol-4,5-bisphosphate 3-kinase
Pih1/Nop17
nucleolus homologous protein 17
PP5
protein phosphatase 5
p-p85
phosphorylated p85
PS-341
proteasome inhibitor
pS6
phosphorylated ribosome protein S6
pSTAT3
phosphorylated signal transducer and activator of transcription 3
PTACH
HDAC inhibitor
PU-H71
Hsp90 inhibitor
Rad51
DNA double strand break repair gene
Raf
rapidly accelerated fibrosarcoma gene
RAS
Ras gene
RTKs
receptor tyrosine kinases
RIP
receptor-interaction proteins
SCC
squamous cell carcinoma
SH-1242
analogue of deguelin
SN38
an antineoplastic drug and is the active metabolite of irinotecan
SNX-5422
Hsp90 inhibitor
Src
Src family kinase
STA-8666
Hsp90 inhibitor
STA-1474
Hsp90 inhibitor
T790M
the 790th site of EGFR exon 20
Tah1
TPR7-containing protein associated with Hsp90
TGF
transforming growth factor
TNF
tumor necrosis factor
TP
thymidine phosphorylase
TRAP1
TNF receptor associated protein 1
unc45b
unc45 myosin chaperone b
VEGF
vascular endothelial growth factor
WK88-1
Hsp90 inhibitor
XRCC1
X-ray repair cross-complement group 1 protein
Yes
Src family tyrosine kinase
ReferencesBiaoxueRXiguangCHuaLShuanyingYStathmin-dependent molecular targeting therapy for malignant tumor: The latest 5 years' discoveries and developmentsJ Transl Med14279201610.1186/s12967-016-1000-zBiao-xueRXi-guangCShuan-yingYWeiLZong-juanMEphA2-dependent molecular targeting therapy for malignant tumorsCurr Cancer Drug Targets1110821097201110.2174/15680091179807305021933105BiaoxueRHuaLWenlongGShuanyingYOverexpression of stathmin promotes metastasis and growth of malignant solid tumors: A systemic review and meta-analysisOncotarget778994790072016278063435346693TatokoroMKogaFYoshidaSKiharaKHeat shock protein 90 targeting therapy: State of the art and future perspectiveEXCLI J1448582015266007414652636ChehabMCazaTSkotnickiKLandasSBratslavskyGMollapourMBourbouliaDTargeting Hsp90 in urothelial carcinomaOncotarget684548473201510.18632/oncotarget.3502259092174496161HallJAForsbergLKBlaggBSAlternative approaches to Hsp90 modulation for the treatment of cancerFuture Med Chem615871605201410.4155/fmc.14.89253673924406230ProdromouCMechanisms of Hsp90 regulationBiochem J47324392452201610.1042/BCJ20160005275152564980810KhuranaNBhattacharyyaSHsp90, the concertmaster: Tuning transcriptionFront Oncol5100201510.3389/fonc.2015.00100259733974412016LianosGDAlexiouGAManganoAManganoARauseiSBoniLDionigiGRoukosDHThe role of heat shock proteins in cancerCancer Lett360114118201510.1016/j.canlet.2015.02.02625721081BiaoxueRXilingJShuanyingYWeiZXiguangCJinsuiWMinZUpregulation of Hsp90-beta and annexin A1 correlates with poor survival and lymphatic metastasis in lung cancer patientsJ Exp Clin Cancer Res3170201210.1186/1756-9966-31-70229294013444906KimSHJiJHParkKTLeeJHKangKWParkJHHwangSWLeeEHChoYJJeongYYHigh-level expression of Hsp90β is associated with poor survival in resectable non-small-cell lung cancer patientsHistopathology67509519201510.1111/his.1267525704653MiyataYYaharaIThe 90-kDa heat shock protein, HSP90, binds and protects casein kinase II from self-aggregation and enhances its kinase activityJ Biol Chem2677042704719921551911RongBZhaoCLiuHMingZCaiXGaoWYangSIdentification and verification of Hsp90-beta as a potential serum biomarker for lung cancerAm J Cancer Res48748852014255208754266719PillaiRNRamalingamSSHeat shock protein 90 inhibitors in non-small-cell lung cancerCurr Opin Oncol26159164201410.1097/CCO.000000000000004724463348PennisiRAscenziPDi MasiAHsp90: A new player in DNA repair?Biomolecules525892618201510.3390/biom5042589265013354693249MaloneyAWorkmanPHSP90 as a new therapeutic target for cancer therapy: The story unfoldsExpert Opin Biol Ther2324200210.1517/14712598.2.1.311772336LiJBuchnerJStructure, function and regulation of the hsp90 machineryBiomed J36106117201310.4103/2319-4170.11323023806880VermaSGoyalSJamalSSinghAGroverAHsp90: Friends, clients and natural foesBiochimie127227240201610.1016/j.biochi.2016.05.01827295069ZhangLFokJHDaviesFEHeat shock proteins in multiple myelomaOncotarget511321148201410.18632/oncotarget.1584246752904012740GarcíaRMerinoDGómezJMNistalJFHurléMACortajarenaALVillarAVExtracellular heat shock protein 90 binding to TGFβ receptor I participates in TGFβ-mediated collagen production in myocardial fibroblastsCell Signal2815631579201610.1016/j.cellsig.2016.07.003ProdromouCSiligardiGO'BrienRWoolfsonDNReganLPanaretouBLadburyJEPiperPWPearlLHRegulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain co-chaperonesEMBO J18754762199910.1093/emboj/18.3.75499274351171168RichterKMuschlerPHainzlOReinsteinJBuchnerJSti1 is a non-competitive inhibitor of the Hsp90 ATPase Binding prevents the N-terminal dimerization reaction during the ATPase cycleJ Biol Chem2781032810333200310.1074/jbc.M21309420012525481ObermannWMSondermannHRussoAAPavletichNPHartlFUIn vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysisJ Cell Biol143901910199810.1083/jcb.143.4.90198177492132952SilversteinAMGalignianaMDChenMSOwens-GrilloJKChinkersMPrattWBProtein phosphatase 5 is a major component of glucocorticoid receptor hsp90 complexes with properties of an FK506-binding immunophilinJ Biol Chem2721622416230199710.1074/jbc.272.26.162249195923WandingerSKSuhreMHWegeleHBuchnerJThe phosphatase Ppt1 is a dedicated regulator of the molecular chaperone Hsp90EMBO J25367376200610.1038/sj.emboj.7600930164079781383513PirklFBuchnerJFunctional analysis of the Hsp90-associated human peptidyl prolyl cis/trans isomerases FKBP51, FKBP52 and Cyp40J Mol Biol308795806200110.1006/jmbi.2001.459511350175SrikakulamRLiuLWinkelmannDAUnc45b forms a cytosolic complex with Hsp90 and targets the unfolded myosin motor domainPLoS One3e2137200810.1371/journal.pone.0002137184780962377097ZhaoRKakiharaYGribunAHuenJYangGKhannaMCostanzoMBrostRLBooneCHughesTRMolecular chaperone Hsp90 stabilizes Pih1/Nop17 to maintain R2TP complex activity that regulates snoRNA accumulationJ Cell Biol180563578200810.1083/jcb.200709061182681032234237HesslingMRichterKBuchnerJDissection of the ATP-induced conformational cycle of the molecular chaperone Hsp90Nat Struct Mol Biol16287293200910.1038/nsmb.156519234467LiJSorokaJBuchnerJThe Hsp90 chaperone machinery: Conformational dynamics and regulation by co-chaperonesBiochim Biophys Acta1823624635201210.1016/j.bbamcr.2011.09.003YardenYSliwkowskiMXUntangling the ErbB signalling networkNat Rev Mol Cell Biol2127137200110.1038/3505207311252954XuWMimnaughERosserMFNicchittaCMarcuMYardenYNeckersLSensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90J Biol Chem27637023708200110.1074/jbc.M006864200SchwartzbergPLThe many faces of Src: Multiple functions of a prototypical tyrosine kinaseOncogene1714631468199810.1038/sj.onc.12021769779992PerdewGHWiegandHVanden HeuvelJPMitchellCSinghSSAA 50 kilodalton protein associated with raf and pp60(v-src) protein kinases is a mammalian homolog of the cell cycle control protein cdc37Biochemistry3636003607199710.1021/bi96125299132011DhillonASHaganSRathOKolchWMAP kinase signalling pathways in cancerOncogene2632793290200710.1038/sj.onc.121042117496922StancatoLFChowYHOwens-GrilloJKYemAWDeibelMRJrJoveRPrattWBThe native v-Raf hsp90 p50 heterocomplex contains a novel immunophilin of the FK506 binding classJ Biol Chem269221572216119947520912MiyataYYaharaIInteraction between casein kinase II and the 90-kDa stress protein, HSP90Biochemistry3481238129199510.1021/bi00025a0197794926HoltSEAisnerDLBaurJTesmerVMDYMOuelletteMTragerJBMorinGBToftDOShayJWFunctional requirement of p23 and Hsp90 in telomerase complexesGenes Dev13817826199910.1101/gad.13.7.81710197982316592DeZwaanDCToogunOAEchtenkampFJFreemanBCThe Hsp82 molecular chaperone promotes a switch between unextendable and extendable telomere statesNat Struct Mol Biol16711716200910.1038/nsmb.1616195259722744139SarkarSDuttaDSamantaSKBhattacharyaKPalBCLiJDattaKMandalCMandalCOxidative inhibition of Hsp90 disrupts the super-chaperone complex and attenuates pancreatic adenocarcinoma in vitro and in vivoInt J Cancer132695706201310.1002/ijc.27687SongXWangXZhuoWShiHFengDSunYLiangYFuYZhouDLuoYThe regulatory mechanism of extracellular Hsp90{alpha} on matrix metalloproteinase-2 processing and tumor angiogenesisJ Biol Chem2854003940049201010.1074/jbc.M110.181941209378163000986WalerychDGutkowskaMKlejmanMPWawrzynowBTraczZWiechMZyliczMZyliczAATP binding to Hsp90 is sufficient for effective chaperoning of p53 proteinJ Biol Chem2853202032028201010.1074/jbc.M110.112110206889132952203ParkSJBorinBNMartinez-YamoutMADysonHJThe client protein p53 adopts a molten globule-like state in the presence of Hsp90Nat Struct Mol Biol18537541201110.1038/nsmb.2045214608463087862ZhangQZhaiSLiLLiXZhouHLiuASuGMuQDuYYanBAnti-tumor selectivity of a novel tubulin and HSP90 dual-targeting inhibitor in non-small cell lung cancer modelsBiochem Pharmacol86351360201310.1016/j.bcp.2013.05.01923743233ZhangLYuZWangYWangXZhangLWangCYueQWangXDengSHuoXQuantitative proteomics reveals molecular mechanism of gamabufotalin and its potential inhibition on Hsp90 in lung cancerOncotarget776551765642016273848785363529SuJMHsuYYLinPChangHNuclear accumulation of heat-shock protein 90 is associated with poor survival and metastasis in patients with non-small cell lung cancerAnticancer Res3621972203201627127123Gallegos RuizMIFloorKRoepmanPRodriguezJAMeijerGAMooiWJJassemENiklinskiJMuleyTvan ZandwijkNIntegration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential targetPLoS One3e0001722200810.1371/journal.pone.0001722183200232254495LiuWWuYWangLGaoLWangYLiuXZhangKSongJWangHBayerTAProtein signature for non-small cell lung cancer prognosisAm J Cancer Res42562692014249593804065406Gomez-CasalREpperlyMWWangHProiaDAGreenbergerJSlevinaVRadioresistant human lung adenocarcinoma cells that survived multiple fractions of ionizing radiation are sensitive to HSP90 inhibitionOncotarget64430644322201510.18632/oncotarget.6248265172404792558LiuTWangXZhangLThe correlation between the up-regulation of Hsp90 and drug resistance to cisplatin in lung cancer cell lineZhongguo Fei Ai Za Zhi144724772011In Chinese21645448SenjuMSueokaNSatoAIwanagaKSakaoYTomimitsuSTominagaMIrieKHayashiSSueokaEHsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell linesJ Cancer Res Clin Oncol132150158200610.1007/s00432-005-0047-7WuYHuangBLiuQLiuYHeat shock protein 90-β over-expression is associated with poor survival in stage I lung adenocarcinoma patientsInt J Clin Exp Pathol88252825920154555722WangMFengLLiPHanNGaoYXiaoTHsp90AB1 protein is overexpressed in non-small cell lung cancer tissues and associated with poor prognosis in lung adenocarcinoma patientsZhongguo Fei Ai Za Zhi1964692016In Chinese26903158ShiYLiuXLouJHanXZhangLWangQLiBDongMZhangYPlasma levels of heat shock protein 90 alpha associated with lung cancer development and treatment responsesClin Cancer Res2060166022201410.1158/1078-0432.CCR-14-017425316816WangYQShenAJSunJYWangXLiuHCZhangMMChenDQXiongBShenJKGengMYTargeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cellsActa Pharmacol Sin3715871596201610.1038/aps.2016.85276165745260832GaponovaAVNikonovaASDenekaAYKoppMCKudinovAESkobelevaNKhazakVOgawaLSCaiKQDuncanKEA novel HSP90 inhibitor-drug conjugate to Sn38 is highly effective in small cell lung cancerClin Cancer Res2251205129201610.1158/1078-0432.CCR-15-3068272678505065742NiuBLinJFengTEffects of 17-AAG on the proliferation and apoptosis of human lung cancer A549 and H446 cellsZhonghua Jie He He Hu Xi Za Zhi382672722015In Chinese26268232HirakawaHFujisawaHMasaokaANoguchiMHirayamaRTakahashiMFujimoriAOkayasuRThe combination of Hsp90 inhibitor 17AAG and heavy-ion irradiation provides effective tumor control in human lung cancer cellsCancer Med4426436201510.1002/cam4.377255821134380968ZhangQZhaiSLiLLiXJiangCZhangCYanBP-glycoprotein-evading anti-tumor activity of a novel tubulin and HSP90 dual inhibitor in a non-small-cell lung cancer modelJ Pharmacol Sci1266676201410.1254/jphs.14050FP25185500NormantEPaezGWestKALimARSlocumKLTunkeyCMcDougallJWylieAARobisonKCaliriKThe Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC modelsOncogene3025812586201110.1038/onc.2010.62521258415GallerneCProlaALemaireCHsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2Biochim Biophys Acta183313561366201310.1016/j.bbamcr.2013.02.01423485394SeoYHDiscovery of 2′,4′-dimethoxychalcone as a Hsp90 inhibitor and its effect on iressa-resistant non-small cell lung cancer (NSCLC)Arch Pharm Res3817831788201510.1007/s12272-015-0595-625855012ChoiYJKimSYSoKSBaekIJKimWSChoiSHLeeJCBivonaTGRhoJKChoiCMAUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cellsPLoS One10e0119832201510.1371/journal.pone.0119832257809094363657UenoTTsukudaKToyookaSAndoMTakaokaMSohJAsanoHMakiYMuraokaTTanakaNStrong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancerLung Cancer762631201210.1016/j.lungcan.2011.09.011JangWJJungSKKangJSJeongJWBaeMKJooSHParkGHKunduJKHongYSJeongCHAnti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplificationCancer Sci10512451253201410.1111/cas.12497251176414462346SmithDLAcquavivaJSequeiraMJimenezJPZhangCSangJBatesRCProiaDAThe HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancerTarget Oncol10235245201510.1007/s11523-014-0329-64457934KoizumiHYamadaTTakeuchiSNakagawaTKitaKNakamuraTMatsumotoKSudaKMitsudomiTYanoSHsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesisJ Thorac Oncol710781085201210.1097/JTO.0b013e3182519a2c22592212KobayashiNToyookaSSohJYamamotoHDoteHKawasakiKOtaniHKuboTJidaMUenoTThe anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitorLung Cancer75161166201210.1016/j.lungcan.2011.04.022RiceJWVealJMBarabaszAFoleyBFaddenPScottAHuangKSteedPHallSTargeting of multiple signaling pathways by the Hsp90 inhibitor SnX-2112 in EGFR resistance models as a single agent or in combination with erlotinibOncol Res18229242200910.3727/096504009X1259618965924020225761SongXZhaoZQiXTangSWangQZhuTGuQLiuMLiJIdentification of epipolythiodioxopiperazines HDN-1 and chaetocin as novel inhibitor of heat shock protein 90Oncotarget652635274201510.18632/oncotarget.3029257427914467147ParkKSOhBLeeMHNamKYJinHRYangHChoiJKimSWLeeDHThe HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinibCancer Lett3727581201610.1016/j.canlet.2015.12.01526723875TakeuchiSFukudaKAraiSNanjoSKitaKYamadaTHaraENishiharaHUeharaHYanoSOrgan-specific efficacy of HSP90 inhibitor in multiple-organ metastasis model of chemorefractory small cell lung cancerInt J Cancer13812811289201610.1002/ijc.29858TungCLJianYJSyuJJWangTJChangPYChenCYJianYTLinYWDown-regulation of ERK1/2 and AKT-mediated X-ray repair cross-complement group 1 protein (XRCC1) expression by Hsp90 inhibition enhances the gefitinib-induced cytotoxicity in human lung cancer cellsExp Cell Res334126135201510.1016/j.yexcr.2015.01.01625662161TungCLChiuHCJianYJJianYTChenCYSyuJJWoTYHuangYJTsengSCLinYWDown-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cellsExp Cell Res322345354201410.1016/j.yexcr.2014.02.00224530475WengSHTsengSCHuangYCChenHJLinYWInhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cellsBiochem Pharmacol84126136201210.1016/j.bcp.2012.03.01122480737BaoRLaiCJWangDGQuHYinLZifcakBTaoXWangJAtoyanRSamsonMTargeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancerMol Cancer Ther832963306200910.1158/1535-7163.MCT-09-053819952121KimWYChangDJHennessyBKangHJYooJHanSHKimYSParkHJSeoSYMillsGA novel derivative of the natural agent deguelin for cancer chemoprevention and therapyCancer Prev Res (Phila)1577587200810.1158/1940-6207.CAPR-08-0184LeeSCMinHYChoiHKimHSKimKCParkSJSeongMASeoJHParkHJSuhYGSynthesis and evaluation of a novel deguelin derivative, L80, which disrupts ATP binding to the C-terminal domain of heat shock protein 90Mol Pharmacol88245255201510.1124/mol.114.09688325976766OnoNYamazakiTTsukaguchiTFujiiTSakataKSudaATsukudaTMioTIshiiNKondohOEnhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancerCancer Sci10413461352201310.1111/cas.1223723863134KoJCChenHJHuangYCTsengSCWengSHWoTYHuangYJChiuHCTsaiMSChiouRYHSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cellsRegul Toxicol Pharmacol64415424201210.1016/j.yrtph.2012.10.00323069143AcquavivaJSmithDLSangJFriedlandJCHeSSequeiraMZhangCWadaYProiaDATargeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespibMol Cancer Ther1126332643201210.1158/1535-7163.MCT-12-061523012248KoJCChiuHCSyuJJChenCYJianYTHuangYJWoTYJianYJChangPYWangTJDown-regulation of MSH2 expression by Hsp90 inhibition enhances cytotoxicity affected by tamoxifen in human lung cancer cellsBiochem Biophys Res Commun456506512201510.1016/j.bbrc.2014.11.116LeeKHJangAHYooCG17-allylamino-17-demethoxygel-danamycin and the enhancement of PS-341-induced lung cancer cell death by blocking the NF-kappaB and PI3K/Akt pathwaysAm J Respir Cell Mol Biol53412421201510.1165/rcmb.2014-0186OC25633180QuZDongHXuXFengWYiXCombined effects of 17-DMAG and TNF on cells through a mechanism related to the NF-kappaB pathwayDiagn Pathol870201310.1186/1746-1596-8-70236350993716826SangJAcquavivaJFriedlandJCSmithDLSequeiraMZhangCJiangQXueLLovlyCMJimenezJPTargeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancerCancer Discov3430443201310.1158/2159-8290.CD-12-0440235332654086149GaronEBFinnRSHamidiHDeringJPittsSKamranpourNDesaiAJHosmerWIdeSAvsarEThe HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growthMol Cancer Ther12890900201310.1158/1535-7163.MCT-12-0998234933113681857WangQSunWHaoXLiTSuLLiuXDown-regulation of cellular FLICE-inhibitory protein (Long Form) contributes to apoptosis induced by Hsp90 inhibition in human lung cancer cellsCancer Cell Int1254201210.1186/1475-2867-12-54232565683558364ShimamuraTPereraSAFoleyKPSangJRodigSJInoueTChenLLiDCarreteroJLiYCGanetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancerClin Cancer Res1849734985201210.1158/1078-0432.CCR-11-2967228068773477583OhSHWooJKYaziciYDMyersJNKimWYJinQHongSSParkHJSuhYGKimKWStructural basis for depletion of heat shock protein 90 client proteins by deguelinJ Natl Cancer Inst99949961200710.1093/jnci/djm00717565155WangXJuWRenouardJAdenJBelinskySALinY17-allyl-amino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathwayCancer Res6610891095200610.1158/0008-5472.CAN-05-269816424045WangYLiuHDiaoLPotterAZhangJQiaoYWangJProiaDATailorRKomakiRHsp90 inhibitor ganetespib sensitizes non-small cell lung cancer to radiation but has variable effects with chemoradiationClin Cancer Res2258765886201610.1158/1078-0432.CCR-15-2190273544725135582SegawaTFujiiYTanakaABandoSOkayasuROhnishiKKubotaNRadiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71Int J Mol Med33559564201410.3892/ijmm.2013.1594CamphausenKTofilonPJInhibition of Hsp90: A multitarget approach to radiosensitizationClin Cancer Res1343264330200710.1158/1078-0432.CCR-07-063217671112KollTTFeisSSWrightMHTeniolaMMRichardsonMMRoblesAIBradsherJCapalaJVarticovskiLHSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repairMol Cancer Ther719851992200810.1158/1535-7163.MCT-07-2104186450082671002LaszloAThotalaDHallahanDEMembrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatmentCancer J19238246201310.1097/PPO.0b013e31829a68eb237080713718064SchillingDBayerCLiWMollsMVaupelPMulthoffGRadiosensitization of normoxic and hypoxic h1339 lung tumor cells by heat shock protein 90 inhibition is independent of hypoxia inducible factor-1αPLoS One7e31110201210.1371/journal.pone.0031110LeeJHChoiKJSeoWDJangSYKimMLeeBWKimJYKangSParkKHLeeYSEnhancement of radiation sensitivity in lung cancer cells by celastrol is mediated by inhibition of Hsp90Int J Mol Med27441446201121249311KimWYOhSHWooJKHongWKLeeHYTargeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alphaCancer Res6916241632200910.1158/0008-5472.CAN-08-0505191763992646382BeckTNKorobeynikovVAKudinovAEGeorgopoulosRSolankiNRAndrews-HokeMKistnerTMPépinDPKNicolasEAnti-Müllerian hormone signaling regulates epithelial plasticity and chemoresistance in lung cancerCell Rep16657671201610.1016/j.celrep.2016.06.043273963414956518ProiaDASangJHeSSmithDLSequeiraMZhangCLiuYYeSZhouDBlackmanRKSynergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer modelsInvest New Drugs3022012209201210.1007/s10637-011-9790-6222278283484281TsaiMSWengSHChenHJChiuYFHuangYCTsengSCKuoYHLinYWInhibition of p38 MAPK-dependent excision repair cross-complementing 1 expression decreases the DNA repair capacity to sensitize lung cancer cells to etoposideMol Cancer Ther11561571201210.1158/1535-7163.MCT-11-0684HashidaSYamamotoHShienKOhtsukaTSuzawaKMakiYFurukawaMSohJAsanoHTsukudaKHsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitorsOncol Rep3314991504201510.3892/or.2015.373525607753SawaiAChandarlapatySGreulichHGonenMYeQArteagaCLSellersWRosenNSolitDBInhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxelCancer Res68589596200810.1158/0008-5472.CAN-07-1570181995564011195LeeSCMinHYChoiHBaeSYParkKHHyunSYLeeHJMoonJParkSHKimJYDeguelin analogue SH-1242 inhibits Hsp90 activity and exerts potent anticancer efficacy with limited neurotoxicityCancer Res76686699201610.1158/0008-5472.CAN-15-1492YangYCChengTYHuangSMSuCYYangPWLeeJMChenCKHsiaoMHuaKTKuoMLCytosolic PKM2 stabilizes mutant EGFR protein expression through regulating Hsp90-EGFR associationOncogene3533873398201610.1038/onc.2015.397ChenZAkbayEMikseOTupperTChengKWangYTanXAltabefAWooSAChenLCo-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistanceClin Cancer Res2012041211201410.1158/1078-0432.CCR-13-17333947539TanimotoAYamadaTNanjoSTakeuchiSEbiHKitaKMatsumotoKYanoSReceptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cellsOncotarget549204928201410.18632/oncotarget.2055249524824148110RolfoCPassigliaFCastigliaMRaezLEGermonprePGil-BazoIZwaenepoelKDe WildeABronteGRussoAALK and crizotinib: After the honeymoon…what else? Resistance mechanisms and new therapies to overcome itTransl Lung Cancer Res32502612014RamalingamSGossGRosellRSchmid-BindertGZaricBAndricZBondarenkoIKomovDCericTKhuriFA randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)Ann Oncol2617411748201510.1093/annonc/mdv22025997818SocinskiMAGoldmanJEl-HariryIKoczywasMVukovicVHornLPascholdESalgiaRWestHSequistLVA multi-center phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancerClin Cancer Res1930683077201310.1158/1078-0432.CCR-12-3381235538493874465SequistLVGettingerSSenzerNNMartinsRGJännePALilenbaumRGrayJEIafrateAJKatayamaRHafeezNActivity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancerJ Clin Oncol2849534960201010.1200/JCO.2010.30.8338209401884676802
Molecular structure and function domain of Hsp90. (A) Hsp90α, Hsp90β, gp96 and the TRAP1 are four members of Hsp90 family 4. (B) Each protomer of Hsp90 comprises three regions, ATP-binding domain (N-domain), middle domain (M-do-main), and C-terminal dimerization domain (C-do-main); the 25-kDa N-terminal of Hsp90 is relatively conserved, which is linked with 55 kDa C-terminal domains by a charged linker region; the N-terminal domain of Hsp90 combined with ATP is intimately tied up with a middle domain via an unstructured charged linker, and the C-terminal domain; the middle domain of Hsp90 is ~35 kDa, and a binding site for client proteins and nuclear localization signal, which is implicated in recognising of collaborating proteins and adjusting the activation molecular chaperones. (C) Hsp90α and Hsp90β, exist as a result of the duplication of the original gene and share 86% homology; the chromosome 14q32.33 encodes the Hsp90α, while Hsp90β is located at 6p21. Hsp90-coding genes include intron sequences and the second exon is the region of translational initiation of both Hsp90α and Hsp90β. Hsp90, heat shock protein 90; TRAP1, TNF receptor associated protein 1; ATP, adenosine-triphosphate.
Co-chaperons and client proteins of Hsp90. (A) More than 20 different proteins regulate the activity and function of Hsp90, which are known as co-chaperones and these proteins regulate the chaperoning function of Hsp90 by activating and inhibiting the activity of Hsp90 ATPase and sometimes by recruiting the specific client proteins; some key co-chaperones include Hop/Sti1, Cdc37, p23/Sba1, PP5, Fkbp51, Fkbp52, Cyp40, unc45b, Tah1, Aha1 and CHIP. (B) The specific co-chaperones of Hsp90 could have a specific intimate relationship with one, even more than one client protein and participate in a series of specific biological reactions; some key co-chaperones include ErbB2/HER2, IGF-I and TGF receptor I and II; the members of Src family, Yes, Fes, Fps, Abl and Lck; ERK1, ERK2, Raf1, B-Raf, Cdk4, Cdk6, hTERT, MMP2, p53, CK2, MOK, MAK, MRK, DAPK. Hsp90, heat shock protein 90; ATPase, adenylpyrophosphatase; Hop/Sti1, a co-chaperone adaptor protein for Hsp90; Cdc37, cell division cycle 37; p23/Sba1, the protein encoded by the PTGES3 gene; PP5, protein phosphatase 5; Fkbp51 and Fkbp52, Hsp90-associated human peptidyl prolyl cis/trans isomerases; Cyp40, cyclophilin 40; unc45b, unc45 myosin chaperone b; Tah1, TPR7-containing protein associated with Hsp90; Aha1, activator of Hsp90 ATPase; CHIP, carboxyl-terminus of the Hsp70 interacting protein; ErbB2/HER2, human epidermal growth factor receptor-2; IGF-I, insulin-like growth factor 1; TGF, transforming growth factor; Yes, Fes, Fps, Abl and Lck, some of Src family tyrosine kinases; ERK, extracellular-signal-regulated kinase; Raf, rapidly accelerated fibrosarcoma gene; Cdk, cyclin-dependent kinase; hTERT, human telomerase reverse transcriptase; MMP2, matrix metalloproteinase-2; p53, tumor suppressor p53; CK2, casein kinase 2; MOK, MAK and MRK, MAPK-related protein kinases; DAPK, death associated protein kinase.
Influence of Hsp90 on the cell cycle regulation and cell apoptosis. Inhibition of Hsp90 induces G2/M phase arrest of lung cancer cells by reducing the expression of Cdc2 and Cdc25C and promotes apoptosis via a caspase-dependent pathway; inhibition of Hsp90 induces an effective cell cycle arrest, which is associated with DNA damage and cell cycle checkpoints, and apoptosis by regulating the expression of Bax and Bcl-2. Inhibition of Hsp90 causes the destabilization of microtubules and degradation of CRAF-1 and ERBB2 and phosphorylated AKT, leading to cell cycle arrest at the G2/M phase and reinforcement of apoptosis. Hsp90 inhibition leads to disruption of EML4-ALK and induces growth arrest and apoptosis in lung cancer cells. Hsp90 inhibition upregulates Grp94, Grp78, ATF4 and CHOP and induces apoptosis of lung cancer cells by downregulation of Bcl-2, upregulation of Bax, release of cytochrome c and activation of caspases. Hsp90, heat shock protein 90; Cdc2, cell division cycle 2; Cdc25C, cell division cycle 25C; DNA, deoxyribonucleic acid; Bax, bcl-2-like protein 4; Bcl-2, B-cell lymphoma-2; CRAF-1, threonine protein kinase; ERBB2, human epidermal growth factor receptor-2; AKT, anaplastic lymphoma kinase; EML4-ALK, echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase; Grp94, glucose-regulated protein 94; Grp78, glucose-regulated protein 78; ATF4, anti-activating transcription factor 4; CHOP, nuclear transcription factor.
Influence of Hsp90 on the growth of lung cancer via EGFR signaling pathways. Hsp90 inhibition decreases the growth of NSCLC cells by down-regulating EGFR, Met, Her2, Akt, and Cdk4, and upregulating Hsp70, and inhibits the proliferation and induces cell death by downregulation of EGFR and AXL. Hsp90 inhibition results in exhaustion of EGFR, Met, HER2 and AKT, which leads to the reinforcement of apoptosis; Hsp90 inhibition reduces the lung cancer cell survival via reducing the expression of EGFR, ErbB2, ErbB3, Met and Akt. Hsp90 inhibition and erlotinib stabilizes the expression state of EGFR inactivation and disrupts ERK and AKT signaling activity, which is associated with downregulation of EGFR and Met. Inhibition of Hsp90 exhausts EGFR, AKT, MAPK, Cdk4, and cyclin D1 and suppresses EGF activation of pAKT(473) and pSTAT3(705), pERK1/2 and pS6 and causes c-Met degradation; suppression of Hsp90 reduces expression of Hsp90-dependent client protein EGFR and results in a potential conformational change and degrades multiple oncoproteins and promotes EGF-induced wild-type and mutated EGFR downregulation. Hsp90, heat shock protein 90; EGFR, epidermal growth factor receptor; CDK4, cyclin-dependent kinase 4; ERBB, human epidermal growth factor receptor; AKT, anaplastic lymphoma kinase; Met, Met gene; Her2, human epidermal growth factor receptor-2; AXL, receptor tyrosine kinase; ERK, extracellular-signal-regulated kinase; MAPK, mitogen-activated protein kinase; EGF, epidermal growth factor; STAT3, signal transducer and activator of transcription 3; c-Met, proto-oncogene.
Hsp90 regulates the growth of lung cancer via RAS-RAF-MEK-ERK-MAPK, PI3K/AKT, TGF and VEGF signaling pathways. Hsp90 inhibition inhibits the signals of PI3K-AKT-mTOR and RAF-MEK-ERK and thus impedes the growth and proliferation of NSCLC cells. Inhibition of Hsp90 reduces the survival ability of SCLC cells via downregulating expression of proto-oncogene c-RAF and inactivation of ERK1/2 and AKT as well as the reduction of XRCC1. Hsp90 inhibition leads to cytotoxic effect to NSCLC cells and accompanies with the reduction of MSH2 via downregulation of the MKK3/6-p38 MAPK signal and inactivation of p38 MAPK and leads to downregulation of cellular TP via a ubiquitin-26S proteasome pathway, which is accompanied by a downregulation of phosphorylated MKK1/2-ERK1/2 and AKT protein levels. Hsp90 inhibition give rise to degradation of RTKs, and disrupts the signaling molecules of the PI3K/AKT and RAF/MEK/ERK pathways. Inhibition of Hsp90 targets IKKβ/NF-κB to prohibit lung cancer growth, and reduces the expressions of hTERT, HIF-1α, VEGF, CDK4, HER2, p-Akt, cyclin D1, p110α and p-p85. Disruption of Hsp90 function leads to the disruption of correlation between HIF-1α and Hsp90 by reducing HIF-1α, VEGF and IGF2. Hsp90 inhibition abolishes phosphorylation of Stat3 and give rise to downregulation of ERK signaling. Hsp90 inhibition cuts down the levels of Rad51, phosphorylated MKK1/2-ERK1/2 and damages the correlation of Hsp90 and Rad51 and leads to a remarkable cytotoxic activity via destabilization of KRAS signaling. Hsp90, heat shock protein 90; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; AKT, anaplastic lymphoma kinase; mTOR, mammalian target of rapamycin; RAF, rapidly accelerated fibrosarcoma gene; MEK, mitogen-activated protein kinase; ERK, extracellular-signal-regulated kinase; c-RAF, threonine protein kinase; XRCC1, X-ray repair cross-complement group 1 protein; MKK3, a dual-specificity protein kinase of the STE7 family; MAPK, mitogen-activated protein kinase; TP, thymidine phosphorylase; RTKs, receptor tyrosine kinases; IKKβ, inhibitor of nuclear factor κB kinase; NF-κB, nuclear factor κB; hTERT, human telomerase reverse transcriptase; HIF-1α, hypoxia-inducible factor-1; VEGF, vascular endothelial growth factor; HER2, human epidermal growth factor receptor-2; p110α, enhanced phosphoinositide 3-kinase; IGF2, insulin-like growth factor 2; Rad51, DNA double strand break repair gene.
New signaling pathways of inhibition of Hsp90 for regulating the growth of lung cancer. Hsp90 inhibition downregulates the expression of MSH2 and tamoxifen combined with Hsp90 inhibition give rise to cytotoxicity and cell growth inhibition synergistically in NSCLC cells via reducing MSH2 expression. Hsp90 inhibition enhances PS-341-induced lung cancer cell death by degrading IκB, IRAK-1 and IKKs. Combination treatments of Hsp90 inhibition and TNF brings about synergistic killing of lung cancer cells via downregulation of IKKβ. Hsp90 inhibition induces loss of EML4-ALK expression and depletion of multiple oncogenic signaling proteins in ALK-driven NSCLC cells. Hsp90 inhibition disintegrates the relation of Hsp90 with p23 and depletion of Hsp90α/β decreases c-FLIPL level and combination of Hsp90 inhibition and celecoxib reinforces this effect by caspase activation, and leads to ubiquitin-mediated degradation of HIF-1α. Combination of Hsp90 inhibition and TNF induces apoptosis-related cell death of lung cancer cells by degradation of RIP and IKKβ and blocking of TNF-induced NF-κB activation. Hsp90, heat shock protein 90; MSH2, human MutS homolog 2; PS-341, a potent proteasome inhibitor; IκB, IκB kinase; IRAK-1, IL-1R-associated kinase-1; IKKs, IκB kinases; IKKβ, inhibitor κB kinase β; EML4-ALK, echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase; ALK, anaplastic lymphoma kinase; c-FLIPL, cellular FLICE-inhibitory protein; p23, important co-chaperone for the Hsp90; HIF-1α, hypoxia-inducible factor-1; RIP, receptor-interaction proteins.
Hsp90 expression in human lung cancer and correlation with clinical outcome.
Authors/Refs.
Lung cancer classification
Cell lines
Tissue
Blood
Techniques
Notes
Biaoxue Rong et al (10)
Lung cancer
Yes
Yes
No
IHC, WB
The upregulation of Hsp90β is associated with poor post-surgical survival time and lymphatic metastasis of lung cancer patients
Rong et al (13)
Lung cancer
No
Yes
Yes
IHC, ELISA
Upregulation of serum Hsp90β is associated with pathological grade and clinical stage of lung cancer patients
Su et al (46)
NSCLC
No
Yes
No
IHC
Nuclear accumulation of Hsp90 might be a predictor of metastasis and survival in patients with NSCLC
Gallegos et al (47)
NSCLC
Yes
Yes
No
Genomic hybridization
The survival patients whose tumors have low expression levels of Hsp90 is also longer and low Hsp90 expression to be related with longer overall survival
Liu et al (48)
NSCLC
No
Yes
No
PPA
Overexpression of Hsp90 in NSCLC correlates with a favorable overall survival in all NSCLC patients
Gomez-Casal et al (49)
NSCLC
Yes
No
No
IHC, WB, qRT-PCR
Hsp90 protein is present at high levels in parental T2821 and T2851 cells as well as in radioresistant T2821/R and T2851/R cells of lung cancer
Senju et al (51)
Lung cancer
Yes
Yes
No
IHC,WB, qRT-PCR
Remarkable high expression of Hsp90 protein in lung cancer cell lines and a more intense signal for Hsp90 by IHC in males, patients with smoking index over 600, and squamous cell carcinoma are observed
Wu et al (52)
NSCLC
No
Yes
No
IHC, WB
Hsp90-β protein is overexpressed in lung adenocarcinoma tumor tissues and correlates with poor outcomes in early stage ADC patients and low pathological grade tumors
Wang et al (53)
NSCLC
No
Yes
No
IHC
Hsp90β protein is overexpressed in NSCLC tissues, and is associated with lung cancer pathological type and overall survival in lung adenocarcinoma patients
Shi et al (54)
NSCLC
No
No
Yes
ELISA
Plasma Hsp90α protein levels are useful as a diagnostic biomarker in lung cancer and predict the responses of patients with lung cancer to chemotherapy
ADC, adenocarcinoma; ELISA, enzyme-linked immunosorbent assay; IHC, immunohistochemistry; ISH, in situ hybridization; NSCLC, non-small cell lung cancer; PPA, protein pathway array; qRT-PCR, real-time quantity PCR; WB, western blotting.
The research progress of Hsp90 and anti-lung cancer drugs.
Authors/Refs.
Type of lung cancer
Cell lines
Anticancer drugs
Notes
Gomez-Casal et al (49)
NSCLC
T2821, T2851
Cisplatin
Hsp90 inhibition can potentiate the effect of radiotherapy and eliminate radioresistant and cisplatin-resistant residual cells
Wang et al (55)
NSCLC
HCC827/GR6, NCI-H1650, NCI-H1975
Gefitinib
Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells
Gaponova et al (56)
SCLC
NCI-H69, NCI-H157
Carboplatin
STA-8666 strongly enhances the action of carboplatin
Zhang et al (59)
NSCLC
H460
Unavailable
CDBT was discovered to have potent antitumor activity in P-gp overexpressing drug-resistant NSCLC H460TaxR cells
Seo (62)
NSCLC
H1975
EGFR TKIs
The 2′,4′-dimethoxychalcone (1b) could serve as a potential therapeutic lead to circumvent the drug resistance acquired by EGFR mutation and Met amplification
Choi et al (63)
NSCLC
HCC827/GR, HCC827/ER
Gefitinib, erlotinib
AUY922 treatment effectively suppresses proliferation and induces cell death in both resistant cell lines
Smith et al (66)
NSCLC
NCI-HCC827, NCI-H1975
Erlotinib, afatinib
Ganetespib potentiates the efficacy of erlotinib in TKI-sensitive, mutant EGFR-driven xenograft tumors and enhances antitumor responses to afatinib
Koizumi et al (67)
NSCLC
H1975 cells, PC-9, Ma-1 cells
Erlotinib
Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs erlotinib in EGFR-mutant lung cancer
Park et al (71)
NSCLC
H23, H358, H647, H1944, A549
Trametinib
The Hsp90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant NSCLC with intrinsic resistance to MEK inhibitor, trametinib
Tung et al (73)
NSCLC
A549, H1975
Gefitinib
Downregulation of ERK1/2 and AKT-mediated XRCC1 expression by Hsp90 inhibition enhances the gefitinib-induced cytotoxicity in human lung cancer cells
Bao et al (76)
NSCLC
H1975, A549
Erlotinib
Hsp90 inhibitor CUDC-305 exhibits durable inhibition of multiple oncoproteins and induction of apoptosis in erlotinib-resistant NSCLC cells
Lee et al (78)
NSCLC
H1299, A549, BEAS-2B
Paclitaxel
L80 shows significant inhibitory effects on the viability, colony formation, angiogenesis-stimulating activity, migration, and invasion of a panel of acquired resistance to paclitaxel lung cells
Ono et al (79)
NSCLC
NCI-H1975
Erlotinib
CH5164840 enhances the antitumor activity of erlotinib against NCI-H292 EGFR-overexpressing xenograft models
Sang et al (85)
NSCLC
H2228, U118-MG
Crizotinib
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in NSCLC
Wang et al (91)
NSCLC
H460, A549, H1299, H1650, H358, H2087
Carboplatin, paclitaxel
Hsp90 inhibitor ganetespib sensitizes NSCLC to radiation but has variable effects with chemoradiation
Beck et al (99)
NSCLC
A549, H1299
Cisplatin
EMT associated with depletion of AMH or AMHR2 results in chemoresistance but sensitizes cells to the Hsp90 inhibitor ganetespib
Hashida et al (102)
NSCLC
HCC827, PC-9
Gefitinib
Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors
Sawai et al (103)
NSCLC
H1650, H1975, H3255
Paclitaxel
Inhibition of Hsp90 downregulates mutant EGFR expression and sensitizes EGFR mutant tumors to paclitaxel
Yang et al (105)
NSCLC
A549, H157, H1355, H1975, HCC827
EGFR TKIs
PKM2 depletion suppresses the growth of TKI-resistant xenografts (H1975) that carried L858R/T790M mutations by interacting with Hsp90
Chen et al (106)
NSCLC
Unavailable
Crizotinib
Hsp90 inhibition (17-DMAG) can overcome both primary and acquired crizotinib resistance
Tanimoto et al (107)
NSCLC
H2228, H3122
Alectinib
Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells
Proia et al (100)
NSCLC
H1975
Paclitaxel, docetaxel
Ganetespib potentiates the cytotoxic activity of paclitaxel and docetaxel in NSCLC models. resulting synergistic antiproliferative effects in vitro and in vivo
Tsai et al (101)
NSCLC
H1975, A549
Etoposide
17-AAG could decrease the etoposide-induced p38 MAPK-mediated ERCC1 expression and augment the cytotoxic effect and growth inhibition by etopsoside
Rolfo et al (108)
NSCLC
Unavailable
Crizotinib
Hsp90 inhibitors may overcome crizotinib resistance by decreasing proper folding of ALK fusion protein